Arkayli Biopharma
Arkayli Biopharma, based in Madison, WI, is dedicated to developing innovative medications utilizing precision drug delivery systems aimed at enhancing treatment efficacy and safety for individuals with vascular anomalies. Their lead product candidate, ARK001, is positioned to be the first FDA-approved non-systemic topical treatment for infantile hemangioma, offering a new approach to care that allows for earlier intervention by pediatricians and dermatologists.
ARK001 is designed to provide a safe and effective localized treatment that minimizes systemic exposure, requiring only a single daily application to deliver 24-hour relief. The formulation is user-friendly, easily washing off with mild soap and water after a day, making it convenient for infants, their families, and caregivers.
Generated from the website
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.
